Multidetector-row computed tomography assessment of adding budesonide/formoterol to tiotropium in patients with chronic obstructive pulmonary disease.

Abstract

BACKGROUND:

In patients with chronic obstructive pulmonary disease (COPD), multidetector-row computed tomography (MDCT) showed that tiotropium dilated the inner diameters in airways from the third to the sixth generation of the bronchi. Here we aimed to evaluate the morphological effect by adding a budesonide/formoterol combination to tiotropium in COPD patients using three-dimensional MDCT.

METHODS:

Pulmonary function tests, St. George's Respiratory Questionnaire (SGRQ) and MDCT imaging studies were performed at the beginning and after budesonide/formoterol combination treatment for 12 weeks in 14 patients with COPD.

RESULTS:

The median age was 73.5 years and the mean forced expiratory volume in 1 s (FEV1) as a percentage of the predicted value was 57.2 ± 18.3%. The luminal area in the fifth generation bronchi and the emphysema volume/CT-derived total lung volume were significantly correlated with FEV1 at baseline (r = 0.682, p < 0.02 and r = -0.868, p < 0.001, respectively). The average luminal area and wall area percentage in the third, fourth and fifth generations were correlated with the SGRQ total score. Budesonide/formoterol induced insignificant pulmonary function changes and significant symptoms improvement. CT images showed an increased inner luminal area and decreased wall area after budesonide/formoterol treatment. Average luminal area was significantly increased from 24.3 ± 9.7 to 26.0 ± 9.9 mm(2) in the third generation, 13.0 ± 6.5 to 14.7 ± 7.3 mm(2) in the fourth generation, 8.0 ± 4.8 to 9.4 ± 4.9 mm(2) in the fifth generation and 5.6 ± 2.7 to 6.7 ± 3.6 mm(2) in the sixth generation (p < 0.01). The average increase of the third generation luminal area was correlated with the FEV1 increase (r = 0.632, p < 0.03). The wall area percentage significantly decreased from 51.5 ± 9.2 to 49.1 ± 9.7 in the third generation, 56.1 ± 9.7 to 53.0 ± 11.1 in the fourth generation, and 62.3 ± 9.9 to 57.6 ± 9.8 in the fifth generation (p < 0.05). Emphysema volume/CT-derived total lung volume was unchanged with treatment.

CONCLUSION:

MDCT demonstrated budesonide/formoterol induced bronchodilation in the non-small airway. CT imaging can evaluate drug therapeutic effect and may provide additional insights into pharmacotherapy for COPD.

• Authors: Hideki Yasui, Naoki Inui, Kazuki Furuhashi, Yutaro Nakamura, Tomohiro Uto, Jun Sato, Kazumasa Yasuda, Yasuo Takehara, Takafumi Suda, Kingo Chida
• Journal: Pulmonary pharmacology & therapeutics (Pulm Pharmacol Ther) Vol. 26 Issue 3 Pg. 336-41 (Jun 2013) ISSN: 1522-9629 [Electronic] England
• PMID: 23340058 (Publication Type: Journal Article)
• Copyright: Copyright © 2013 Elsevier Ltd. All rights reserved.

Chemical References

• Bronchodilator Agents
• Drug Combinations
• Ethanolamines
• Scopolamine Derivatives
• Budesonide
• Formoterol Fumarate
• Tiotropium Bromide

Topics

• Aged
• Aged, 80 and over
• Bronchodilator Agents (administration & dosage, pharmacology, therapeutic use)
• Budesonide (administration & dosage, pharmacology, therapeutic use)
• Drug Combinations
• Ethanolamines (administration & dosage, pharmacology, therapeutic use)
• Female
• Formoterol Fumarate
• Humans
• Lung (diagnostic imaging, physiopathology)
• Male
• Middle Aged
• Multidetector Computed Tomography
• Pilot Projects
• Pulmonary Disease, Chronic Obstructive (drug therapy, physiopathology)
• Respiratory Function Tests
• Scopolamine Derivatives (administration & dosage, pharmacology, therapeutic use)
• Tiotropium Bromide